Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816939 | 1.00 | SCN9A (0.48) | SCN9AKMT2AL3MBTL1NPY1RMME | |
| SCHEMBL24379309 | 1.00 | SCN9A (0.48) | SCN9AKMT2AL3MBTL1NPY1RMME | |
| SCHEMBL4698131 | 0.90 | KMT2A (0.47) | SCN9AKMT2AL3MBTL1 | |
| SCHEMBL4700532 | 0.90 | KMT2A (0.47) | SCN9AKMT2AL3MBTL1 | |
| SCHEMBL9655226 | 0.82 | KMT2A (0.48) | SCN9AKMT2AL3MBTL1NPY1RDRD2 | |
| SCHEMBL9655228 | 0.82 | KMT2A (0.48) | SCN9AKMT2AL3MBTL1NPY1RDRD2 | |
| SCHEMBL7420003 | 0.82 | SCN9A (0.47) | SCN9AKMT2AL3MBTL1NPY1RMME | |
| SCHEMBL19027637 | 0.81 | KMT2A (0.50) | SCN9AKMT2AL3MBTL1NPY1RACE | |
| SCHEMBL18870010 | 0.80 | ALDH1A1 (0.51) | SCN9AKMT2AL3MBTL1NPY1R | |
| SCHEMBL7768791 | 0.80 | KMT2A (0.49) | SCN9AKMT2AL3MBTL1NPY1RMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7325355-B2 | Methods for treatment of atherosclerosis using 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline | CELGENE CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |